Myeloablative conditioning in myelofibrosis using i.v. treosulfan and autologous peripheral blood progenitor cell transplantation with high doses of CD34+ cells results in hematologic responses - follow-up of three patients.
Haematologica
; 90(2): ECR08, 2005 Feb.
Article
em En
| MEDLINE
| ID: mdl-15713582
ABSTRACT
Autologous transplantation after myeloablation for myelofibrosis with myeloid metaplasia provides a palliative therapy with a long term relief of symptoms. We have transplanted three patients with more than 5 x 10(6) CD34+ cells/kg body weight after myeloablation with treosulfan (total dose 42 g/m(2)) with a 18 months follow-up. Two of the patients had symptomatic splenomegaly and severe anemia. One patient had symptomatic splenomegaly and thrombocytopenia (< 100x10(9)/L). Granulocyte colony-stimulating factor-supported peripheral blood progenitor cell mobilization and collection was not associated with increased toxicity. Following transplantation we observed a prolonged reconstitution period of 28-38 days without fever or severe mucositis. All patients became free of erythrocyte transfusions or recovered to normal thrombocyte counts. There was a significant reduction of max. spleen size in one patient. We conclude that myeloablation with treosulfan and autologous PBPCT in these three patients with myelofibrosis was safe and useful.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Bussulfano
/
Antígenos CD34
/
Condicionamento Pré-Transplante
/
Transplante de Células-Tronco de Sangue Periférico
/
Mielofibrose Primária
Idioma:
En
Ano de publicação:
2005
Tipo de documento:
Article